tag:blogger.com,1999:blog-9551150.post5268718632018958080..comments2024-03-28T01:27:23.408-04:00Comments on Health Care Renewal: Who Should Sponsor Comparative Effectiveness Research?Roy M. Poses MDhttp://www.blogger.com/profile/00497209843184497847noreply@blogger.comBlogger7125tag:blogger.com,1999:blog-9551150.post-13124190703654527512009-10-27T15:43:31.423-04:002009-10-27T15:43:31.423-04:00One issue that needs to be addressed is the invest...One issue that needs to be addressed is the investment communities belief that medicine is a growth industry. Time and time again I see information that touts an aging population as the demographic that will drive various companies profits.<br /><br />Along with this there has to be the realization that companies are now run for the benefit of the executives, not their customers (patients) and Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-9551150.post-8288377429048166442009-10-27T12:19:39.213-04:002009-10-27T12:19:39.213-04:00The concept of using EMR data further complicates ...The concept of using EMR data further complicates the issue of CER.<br /><br />See the essay I wrote <a href="http://www.jpands.org/vol14no2/silverstein.pdf" rel="nofollow">here</a> (PDF).<br /><br />ScotInformaticsMDhttps://www.blogger.com/profile/03994321680366572701noreply@blogger.comtag:blogger.com,1999:blog-9551150.post-26159165602366895802009-10-27T11:54:05.048-04:002009-10-27T11:54:05.048-04:00Dr Gaulte -
Exactly!
What is striking is that...Dr Gaulte - <br /><br />Exactly! <br /><br />What is striking is that in this instance the regulatory capture seems to have been built into the governance structure of this organization (at least, as proposed in this version of the bill). <br /><br />It seems like some Senators see CEOs of big health care corporations as a constituency for a comparative effectiveness institute.<br /><br />IMHO,Roy M. Poses MDhttps://www.blogger.com/profile/00497209843184497847noreply@blogger.comtag:blogger.com,1999:blog-9551150.post-18999031052975426432009-10-27T11:18:35.916-04:002009-10-27T11:18:35.916-04:00My major concern about CER is that the process wil...My major concern about CER is that the process will be subject to a version of "regulatory capture" in which vested interests would play a key (perhaps determinative) role in making the decisions.The currently proposed organization you describe seems to be one certain vested interests would relish.james gaultehttps://www.blogger.com/profile/05537303135780186926noreply@blogger.comtag:blogger.com,1999:blog-9551150.post-75690453696514919252009-10-27T10:32:54.303-04:002009-10-27T10:32:54.303-04:00Ultimately if CER or EBM is to work you need relia...Ultimately if CER or EBM is to work you need reliable studies with hard information. This is not the case with a number of currently used drug that have been tested to a surrogate end point as pointed out by Matthew Perrone's AP story Unproven drugs stay on market.<br /><br />Using the "accelerated approval" we find "And the agency (FDA) has never pulled a drug off the market Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-9551150.post-57657417876545040722009-10-26T17:13:54.597-04:002009-10-26T17:13:54.597-04:00Just my own views (MedInformaticsMD) on a PBM cond...Just my own views (MedInformaticsMD) on a PBM conducting comparative effectiveness studies. Leaves some basic questions not covered in the press release (http://medco.mediaroom.com/index.php?s=43&item=403) and not made clear at clintrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00995514?term=NCT00995514&rank=1).<br /><br />Who's actually doing the legwork and what experience InformaticsMDhttps://www.blogger.com/profile/03994321680366572701noreply@blogger.comtag:blogger.com,1999:blog-9551150.post-50465155252962788952009-10-26T15:44:36.573-04:002009-10-26T15:44:36.573-04:00Dr. Poses:
I'm curious to know your perspecti...Dr. Poses:<br /><br />I'm curious to know your perspective on comparative effectiveness research conducted by a PBM. As I discuss on my blog last week, Medco Health Solutions announced its intention to launch a comparative effectiveness study of Bristol-Myers Squibb’s Plavix versus Eli Lilly’s Effient. See <a href="http://www.drugchannels.net/2009/10/medco-takes-on-eli-lilly.html" rel="Adam J. Fein, Ph.D.https://www.blogger.com/profile/15774296048321605590noreply@blogger.com